Seattle Genetics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.12.23	PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer (PR Newswire)
14.12.23	Pfizer Closes $43 Bln All-cash Acquisition Of Seagen (RTTNews)
12.12.23	Pfizer Receives All Required Regulatory Approvals To Complete Seagen Acquisition (RTTNews)
06.12.23	Seagen: HER2CLIMB-02 Study Results Reinforce Clinical Activity Of TUKYSA (RTTNews)
01.12.23	Astellas : FDA Grants Priority Review For SBLA Of Padcev Combination For Bladder Cancer Treatment (RTTNews)
30.11.23	FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer (PR Newswire)
01.11.23	Seagen Inc Q3 Loss increases, misses estimates (RTTNews)
22.10.23	Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-L... (PR Newswire)
22.09.23	Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints (RTTNews)
22.09.23	Seagen Up In Pre-Market After Positive Results From EV-302 Trial (RTTNews)
22.09.23	Seagen, Astellas Pharma Report Positive Topline Results From EV-302 Trial (RTTNews)
22.09.23	PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer i... (PR Newswire)
05.09.23	Genmab : Phase 3 Trial Of TIVDAK In Recurrent Or Metastatic Cervical Cancer Meets Primary Endpoint (RTTNews)
02.08.23	Seagen Inc Q2 Loss increases, misses estimates (RTTNews)
27.04.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, SPPI, HOTH (PR Newswire)
27.04.23	Seagen Inc Q1 Loss increases, misses estimates (RTTNews)
17.04.23	SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates SGEN, UNVR, CVT (PR Newswire)
05.04.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TA, SGEN, UNVR, USX (PR Newswire)
04.04.23	Seagen: FDA Grants Accelerated Approval For Padcev Combination To Treat Metastatic Urothelial Cancer (RTTNews)
03.04.23	FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (PR Newswire)
24.03.23	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, MNTV, JNCE (PR Newswire)
13.03.23	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates PRVB, SGEN, XM (PR Newswire)
13.03.23	Pfizer To Acquire Seagen For $229/shr (RTTNews)
10.03.23	Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic U... (PR Newswire)
27.02.23	Pre-market Movers: MLEC, CFRX, AWIN, TGNA, BRMK… (RTTNews)
27.02.23	Pfizer In Talks To Buy Seagen : Report (RTTNews)
17.02.23	Daiichi Sankyo : U.S. Patent Office Re-Institutes Post Grant Review Of Seagen Patent (RTTNews)
15.02.23	Seagen Inc Q4 Loss decreases, beats estimates (RTTNews)
20.01.23	Seagen : FDA Grants Accelerated Approval To Tukysa Combination For Colorectal Cancer Treatment (RTTNews)
27.12.22	Biotech Stocks Facing FDA Decision In January 2023 (RTTNews)
20.12.22	Astellas: PADCEV, KEYTRUDA Granted Priority Review In Treatment Of Metastatic Urothelial Cancer (RTTNews)
20.12.22	Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment ... (PR Newswire)
10.11.22	Seagen Appoints David Epstein As New CEO (RTTNews)
27.10.22	Seagen Inc Q3 Loss decreases, but misses estimates (RTTNews)
26.10.22	Biotech Stocks Facing FDA Decision In November 2022 (RTTNews)
26.09.22	Seagen, LAVA Therapeutics Ink Worldwide License Agreement To Develop And Commercialize LAVA-1223 (RTTNews)
19.09.22	Seagen: FDA To Review SNDA For Tucatinib In Combination With Trastuzumab (RTTNews)
12.09.22	Seagen, Astellas, Merck: EV-103 Results Support Investigation Of Enfortumab Vedotin, Pembrolizumab (RTTNews)
12.09.22	Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothe... (PR Newswire)
26.08.22	Pre-market Movers: MFGP, LXEH, EVBG, SLNO, SXTC… (RTTNews)
29.07.22	Alnylam Q2 Loss Widens, SGEN Boosts Revenue Outlook, NVCR To Report LUNAR Study Data In Q1 (RTTNews)
28.07.22	Seagen Inc Q2 Loss increases, but beats estimates (RTTNews)
26.07.22	Astellas, Seagen Report Positive Topline Results For Padcev With Keytruda To Treat Urothelial Cancer (RTTNews)
26.07.22	Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer (PR Newswire)
07.07.22	Pre-market Movers: EVTV, USEA, AKUS, GME, ANVS… (RTTNews)
07.07.22	Merck Reportedly In Advanced Talks To Buy Seagen (RTTNews)
23.05.22	Seagen Announces Positive Topline Results Of Phase 2 MOUNTAINEER Trial Of TUKYSA With Trastuzumab (RTTNews)
16.05.22	Seagen Board Accepts Resignation Of Clay Siegall - Quick Facts (RTTNews)
09.05.22	Seagen CEO Clay Siegall Takes Leave Of Absence; Roger Dansey Named Interim Chief (RTTNews)
28.04.22	Seagen Inc Q1 Loss increases, but beats estimates (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’292.00	1.85 %	K V
ABB	50.06	1.17 %	K V
Holcim	89.04	1.09 %	K V
Roche Hldg G	267.00	0.98 %	K V
UBS Group	29.67	0.78 %	K V
Givaudan	3’884.00	-0.49 %	K V
Zurich Insur Gr	547.60	-0.76 %	K V
Geberit	509.20	-0.86 %	K V
Sonova Hldg	294.50	-1.17 %	K V
Logitech Intl	78.88	-1.25 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Seattle Genetics Inc.

Aktien Top/Flop

Meistgelesene Nachrichten